RT Journal Article
T1 SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).
A1 Fernandez-Montes, Ana
A1 Alcaide, Julia
A1 Alsina, Maria
A1 Custodio, Ana Belen
A1 Fernandez-Franco, Lourdes
A1 Gallego-Plazas, Javier
A1 Gomez-Martin, Carlos
A1 Richart, Paula
A1 Rivera, Fernando
A1 Martin-Richard, Marta
K1 Diagnosis
K1 Esophageal cancer
K1 Treatment
AB Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care.
PB Springer
YR 2022
FD 2022-03-26
LK http://hdl.handle.net/10668/21075
UL http://hdl.handle.net/10668/21075
LA en
NO Fernández-Montes A, Alcaide J, Alsina M, Custodio AB, Franco LF, Gallego Plazas J, et al. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):658-669.
DS RISalud
RD Jul 2, 2025